庆祝上市 全新改版

【文摘发布】KIT在小细胞肺癌表达的预后意义

>
Lung Cancer. 2007 Apr 7; [Epub ahead of print]

Prognostic value of KIT expression in small cell lung cancer.

BACKGROUND: Small cell lung cancer (SCLC) is a very aggressive disease, with poor survival rates despite standard treatment with combination chemotherapy with or without radiotherapy. Further insights into the molecular biology of this malignant tumour are needed to improve the therapeutic approaches and outcome. KIT protein is expressed in SCLC, and its kinase activity has been implicated in the pathophysiology of many tumours, including SCLC. The purpose of this study was to evaluate the prevalence of KIT expression in patients with SCLC and its prognostic value. METHODS: We performed an inmunohistochemical analysis of 204 SCLC samples to determine KIT protein expression. The relationship between KIT expression and clinicopathological parameters was evaluated. Univariate and multivariate analyses were performed to define its prognostic significance. RESULTS: KIT expression was observed in 149 of 204 tumour tissues (73%). KIT expression was associated with advanced disease and with decreased incidence of bone metastases. No significant differences were observed for time to disease progression (TTP) (9.1% versus 6.2% at 3 years, p=0.6) or overall survival (OS) (10.7% versus 6.9% at 3 years, p=0.37) among patients with KIT positive versus negative tumours, respectively. Multivariate analysis showed that sex, tumour stage, albumin levels and response to therapy were the only independent predictors for survival. CONCLUSION: KIT protein is expressed in a high percentage of SCLC tumours. In our study population, however, the expression of KIT had no significant impact on survival.

PMID: 17420067 [PubMed - as supplied by publisher]
Lung Cancer. 2007 Apr 7; [Epub ahead of print]

Prognostic value of KIT expression in small cell lung cancer.
KIT在小细胞肺癌表达的预后意义

BACKGROUND: Small cell lung cancer (SCLC) is a very aggressive disease, with poor survival rates despite standard treatment with combination chemotherapy with or without radiotherapy. Further insights into the molecular biology of this malignant tumour are needed to improve the therapeutic approaches and outcome. KIT protein is expressed in SCLC, and its kinase activity has been implicated in the pathophysiology of many tumours, including SCLC.
背景:小细胞肺癌(SCLC)是一种非常有侵袭性的疾病,虽然通过标准治疗加上联合化疗再加上或不加放射治疗,存活率不高。为了改进治疗方法和预后,需要进一步研究这个恶性肿瘤的分子生物学。KIT蛋白在小细胞肺癌中表达,它的激酶活性与许多肿瘤的病理生理学都有联系,包括小细胞肺癌。

The purpose of this study was to evaluate the prevalence of KIT expression in patients with SCLC and its prognostic value.
这项研究的目的是评估在小细胞肺癌患者中KIT表达的普遍性和它的预后价值。

METHODS: We performed an inmunohistochemical analysis of 204 SCLC samples to determine KIT protein expression. The relationship between KIT expression and clinicopathological parameters was evaluated. Univariate and multivariate analyses were performed to define its prognostic significance.
方法:本研究使用免疫组织化学方法(IHC)分析了204例小细胞肺癌组织标本,用来测定KIT蛋白的表达情况。进而评估KIT的表达情况和临床病理资料的之间的联系。再使用单变量分析和多变量分析来评判该蛋白对判断预后的意义

RESULTS: KIT expression was observed in 149 of 204 tumour tissues (73%). KIT expression was associated with advanced disease and with decreased incidence of bone metastases. No significant differences were observed for time to disease progression (TTP) (9.1% versus 6.2% at 3 years, p=0.6) or overall survival (OS) (10.7% versus 6.9% at 3 years, p=0.37) among patients with KIT positive versus negative tumours, respectively. Multivariate analysis showed that sex, tumour stage, albumin levels and response to therapy were the only independent predictors for survival.
结果:在204例肿瘤组织中有149例中有KIT表达(73%)。KIT的表达情况与疾病晚期和减少骨转移的发病率有关。在KIT表达阳性和阴性的肿瘤患者之间,时间分别与疾病的进程 (三年时9.1%vs6.2%, p=0.6)或总体生存数(三年时10.7%vs6.9%, p=0.37)之间无明显差异。多变量分析表明性别、肿瘤分期、白蛋白水平和对治疗的反应分别是对存活率的唯一的独立的预后因子。

CONCLUSION: KIT protein is expressed in a high percentage of SCLC tumours. In our study population, however, the expression of KIT had no significant impact on survival.
结论:KIT蛋白在小细胞肺癌的肿瘤组织中呈高表达。尽管如此,在此次研究的人群中,KIT的表达情况对生存率无明显影响。

PMID: 17420067 [PubMed - as supplied by publisher]

编译:


KIT在小细胞肺癌表达的预后意义

小细胞肺癌(SCLC)是一种非常有侵袭性的疾病,虽然通过标准治疗加上联合化疗再加上或不加放射治疗,存活率仍然不高。因此,为了改进治疗方法和改善预后,需要进一步研究这个恶性肿瘤的分子生物学机制。KIT蛋白能在小细胞肺癌中表达,它的激酶活性与包括小细胞肺癌在内的许多肿瘤的病理生理学都有联系。因此,Lopez-Martin A和他的同事为了评估KIT在小细胞肺癌患者中表达的普遍性和它的判断预后的价值,开展了一项研究,并将其结果发表在《肺癌》杂志中。(Lung Cancer. 2007 Jun;56(3):405-13. Epub 2007 Apr 8.)
该研究使用免疫组织化学方法(IHC)分析了204例小细胞肺癌组织标本,用来测定KIT蛋白的表达情况。进而评估KIT的表达情况和临床病理资料的之间的联系。再使用单变量分析和多变量分析来评判该蛋白对判断预后的意义。结果发现,在204例肿瘤组织中有149例中有KIT表达(73%)。KIT的表达情况与疾病晚期和减少骨转移的发病率有关。在KIT表达阳性和阴性的肿瘤患者之间,时间分别与疾病的进程 (三年时9.1%vs6.2%, p=0.6)或总体生存数(三年时10.7%vs6.9%, p=0.37)之间无明显差异。多变量分析表明性别、肿瘤分期、白蛋白水平和对治疗的反应分别是对存活率的唯一的独立的预后因子。并且进一步得出结论,KIT蛋白在小细胞肺癌的肿瘤组织中呈高表达。尽管如此,在此次研究的人群中,KIT的表达情况对生存率无明显影响。(丁香)

中文字符:506
您的位置:医学教育网 >> 医学资料